Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials
Open Access
- 23 April 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (4), e1983
- https://doi.org/10.1371/journal.pone.0001983
Abstract
Regulatory T lymphocytes (Treg) infiltrate human glioblastoma (GBM); are involved in tumor progression and correlate with tumor grade. Transient elimination of Tregs using CD25 depleting antibodies (PC61) has been found to mediate GBM regression in preclinical models of brain tumors. Clinical trials that combine Treg depletion with tumor vaccination are underway to determine whether transient Treg depletion can enhance anti-tumor immune responses and improve long term survival in cancer patients. Using a syngeneic intracrabial glioblastoma (GBM) mouse model we show that systemic depletion of Tregs 15 days after tumor implantation using PC61 resulted in a decrease in Tregs present in tumors, draining lymph nodes and spleen and improved long-term survival (50% of mice survived >150 days). No improvement in survival was observed when Tregs were depleted 24 days after tumor implantation, suggesting that tumor burden is an important factor for determining efficacy of Treg depletion in clinical trials. In a T cell dependent model of brain tumor regression elicited by intratumoral delivery of adenoviral vectors (Ad) expressing Fms-like Tyrosine Kinase 3 ligand (Flt3L) and Herpes Simplex Type 1-Thymidine Kinase (TK) with ganciclovir (GCV), we demonstrate that administration of PC61 24 days after tumor implantation (7 days after treatment) inhibited T cell dependent tumor regression and long term survival. Further, depletion with PC61 completely inhibited clonal expansion of tumor antigen-specific T lymphocytes in response to the treatment. Our data demonstrate for the first time, that although Treg depletion inhibits the progression/eliminates GBM tumors, its efficacy is dependent on tumor burden. We conclude that this approach will be useful in a setting of minimal residual disease. Further, we also demonstrate that Treg depletion, using PC61 in combination with immunotherapy, inhibits clonal expansion of tumor antigen-specific T cells, suggesting that new, more specific targets to block Tregs will be necessary when used in combination with therapies that activate anti-tumor immunity.Keywords
This publication has 51 references indexed in Scilit:
- Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma modelNeuro-Oncology, 2008
- Regulatory CD4+CD25+T-cells are Controlled by Multiple Pathways at Multiple LevelsInternational Reviews of Immunology, 2007
- Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of miceNature Immunology, 2006
- The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses1Neuro-Oncology, 2006
- An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme1Neuro-Oncology, 2006
- Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor MicroenvironmentClinical Cancer Research, 2005
- Epidemiology and etiology of gliomasActa Neuropathologica, 2005
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Primary brain tumours in adultsThe Lancet, 2003
- The IL-2/IL-2 receptor system: A current overviewCell, 1993